Refine your search
Collections
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Ramya, A.
- Assessment of Appropriate use of Antibiotics in Paediatric Department of A Tertiary Care Teaching Hospital
Abstract Views :186 |
PDF Views:1
Authors
Affiliations
1 Dept. of Pharmacy Practice, School of Pharmaceutical Sciences, Vels University (VISTAS), Velannagar, PV Vaithyalingam Road, Pallavaram, Chennai-600117, Tamil Nadu, IN
1 Dept. of Pharmacy Practice, School of Pharmaceutical Sciences, Vels University (VISTAS), Velannagar, PV Vaithyalingam Road, Pallavaram, Chennai-600117, Tamil Nadu, IN
Source
Research Journal of Pharmacy and Technology, Vol 10, No 2 (2017), Pagination: 381-384Abstract
Aim and objective: To determine the appropriate antibiotic therapy in paediatrics and evaluate the appropriateness of antibiotic treatment.
Methods: A prospective study of 9 months duration was carried out from Aug 2015-April 2016. A total 200 prescriptions were collected. The data was collected using specially designed data entry form and appropriateness is assessed with the help of IAP and NICE guidelines.
Results: Out of 200 patients, 14 were in the age group <1 year, 80 were in between 1-3 years of age, 74 were in the age group of 3-8 years and above 8-12 years were 32. Among study population the disease LRTI was the most common diagnosis in 0-1 year (Infant), AGE was the most common diagnosis in the age group 1-3 years, LRTI was mostly found in the age group of 3-8 years and 8-12 years. Significant difference was found in the age group of patient and disease encountered [p= 0.0008]. The third generation cephalosporin, Cefixime (32%) was mostly used, followed by Metronidazole (25%) and Amoxicillin (16%). The Gentamicin(3%) was given to the least patients.
Conclusion: The study concludes that over 200 prescriptions, it was found that most of the antibiotic therapy in the drug regimen is appropriate to the above mentioned guidelines, only slight variation in the drug regimen seen. It shows that the antibiotic therapy in pediatric ward is appropriate to the guidelines.
- The Role of Leukotriene Receptor Antagonist as an add on therapy to β2-Agonists in Acute Asthma
Abstract Views :170 |
PDF Views:0
Authors
Affiliations
1 School of Pharmaceutical Sciences, Vels University (VISTAS), Pallavaram, Tamil Nadu, IN
2 Department of Surgery, ESIC hospital, Chennai, Tamil Nadu, IN
1 School of Pharmaceutical Sciences, Vels University (VISTAS), Pallavaram, Tamil Nadu, IN
2 Department of Surgery, ESIC hospital, Chennai, Tamil Nadu, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 4 (2019), Pagination: 1974-1978Abstract
Objective:This study was designed to determine the role of leukotriene receptor antagonist as an add on therapy to β2-agonists in acute asthma. Methods: A prospective study carried out in ESIC hospital in which the total number of 100 patients were enrolled. The study has two arms, the group A treated with salbutamol alone and the group B treated with salbutamol and montelukast. The symptomatic changes and variation in pulmonary function test (PFT), pulse rate (PR), respiratory rate (RR) were compared between both the group. The data were collected, compiled, analysed with statistical tools (SPSS – Microsoft Version 6). Results: In comparison of force expiratory volume % (FEV1 PRED) between the group A and group B, after 24 hours significant change was noticed in group B. The results of forced expiratory volume/forced vital capacity (FEV1/FVC%) shows a significant difference after 24 hours of the treatment with salbutamol in group A and salbutamol plus leukotriene receptor antagonist (Montelukast) from the baseline measurement. Base line asthma score shows p value (p = 0.58). But after 48 hours, significant change was noticed in both groups. p value was significant (p = 0.05). In group B, asthma score was significantly improved with passage of time. Conclusion: The study revealed the effectiveness of leukotriene receptor antagonist in preventing many types of aggravated asthmatic responses. Once-daily treatment with 10 mg of montelukast, as compared with β2-agonists, provided significant protection against severe broncho-constriction. Parameters strongly confirmed the role of leukotriene receptor antagonist when in addition added with β2-agonists.Keywords
Leukotriene Receptor Antagonist, Acute Asthma, β2-Agonists.References
- NHLBI Guideline 2007, pp. 11–12
- "Asthma Fact sheet N°307". WHO. November 2013. Archived from the original on June 29, 2011. Retrieved 3 March 2016. "Asthma Fact sheet N°307". WHO. November 2013. Archived from the original on June 29, 2011. Retrieved 3 March 2016.
- Laviolette, M., Malmstrom, K., Lu, S., Chervinsky, P., Pujet, J.C., Peszek, I., Zhang, J. and Reiss, T.F. (1999). Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 160: 1862- 1868.
- Tan TA, Spector SL. Exercise-induced asthma: diagnosis and management. Ann Allergy Asthma Immunol 2002;89:226–36.
- Inman MD, O’Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996;153:65–9.
- Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. Ann Intern 2000;132:97–104.
- Kanniess, F., Richter, K., Böhme, S., Jörres, R.A. and Magnussen, H. (2002). Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J. 20: 853-858.
- National Asthma Education and Prevention Program. (1997). Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health. NIH Publication 97-4051.
- Laviolette, M., Malmstrom, K., Lu, S., Chervinsky, P., Pujet, J.C., Peszek, I., Zhang, J. and Reiss, T.F. (1999). Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 160: 1862-1868.
- Gauvreau, G,M., Parameswaran, K. N., Watson, R.M. and O'Byrne, P.M. (2001) Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med. 164: 1495-1500.
- Barnes, N.C. (2000). Effects of antileukotrienes in the treatment of asthma. Am J Respir Crit Care Med. 161: S73-S76.
- Yoshida, S., Ishizaki, Y., Shoji, T., Onuma, K., Nakagawa, H., Nakabayashi, M., Akahori, K., Hasegawa, H. and Amayasu, H. (2000). Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy. 30: 1008-1014.
- Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet L-P, Wei LX, Efthimiadis AE, Zhang J and Hargreave FE (1999). Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. EurRespir J., 14: 12-18.
- Syed hyderrazanaqvi, Mahayrukh, Farooqalamsiddiqui and asif bin rehman (2011). Role of leukotriene receptor antagonist in acute Severe attack of bronchial asthma in comparison with conventional therapy: Pakistan Journal of Pharmacology.,Vol.28, No.2, July 2011, pp.13-21.
- Carlos A. Camargo, Jr., Howard A. Smithline, Marie-Pierre Malice, Stuart A. Green, and Theodore F. Reiss (2003).A Randomized Controlled Trial of Intravenous Montelukast in Acute Asthma.Am J RespirCrit Care Med Vol 167. pp 528–533, 2003
- Malmstrom, K., Rodriguez-Gomez, G.and Guerra, J. (1999). Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial; Montelukast/Beclomethasone Study Group. Ann Intern Med. 130: 487-495.
- P. Geetha, M. Kousalya, S. Geetha Lakshmi, R. Gopi. Prescribing Pattern of Drugs Used For Respiratory Disease in Pediatric Patients at Private Hospital. Research J. Pharm. and Tech. 9(3): Mar., 2016; Page 251-256.
- A. Ramya, P. Geetha, P. Shanmugasundaram. Assessment of Appropriate use of Antibiotics in Paediatric Department of A Tertiary Care Teaching Hospital. Research J. Pharm. and Tech. 2017; 10(2): 381-384.
- Pavithra H. Dave, Preetha. Pathogenesis and Novel Drug for Treatment of Asthma – A Review. Research J. Pharm. and Tech 2016; 9(9):1519-1523.